Pharmacokinetic and safety evaluation of SangCya vs neoral or sandimmune in stable renal transplant recipients

Transplantation Proceedings

Volumn 31, Issue 1-2, 1999, Pages 326-327

  Gaston, R ^b   Alloway, R R ^b   Gaber, A O ^b   Rossi, S J ^a   Schroeder, T J ^a   Irish, W D ^a   Canafax, D M ^b   First, M R ^b  

^a GENZYME CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0032987103     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)01647-9     Document Type: Conference Paper

References (1)

1. Schroeder T.J., Cho M.J., Pollack G.M., et al. J Clin Pharmacol. 38:1998;807.